title: Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.
abstract: OBJECTIVE
  At least one quarter of ST-segment elevation myocardial infarction (STEMI) patients do not receive reperfusion therapy, and these patients are at high risk for new ischaemic events. We evaluated fondaparinux treatment vs. usual care, i.e. placebo or unfractionated (UF) heparin, in a pre-specified subgroup of 2867 (out of 12 092) patients not receiving reperfusion treatment in the OASIS-6 trial.
  
  
  METHODS
  In all, 1458 patients were randomized to fondaparinux 2.5 mg once daily subcutaneously up to 8 days and 1409 patients to usual care (control). Randomization was stratified by indication for UF heparin (stratum II, n = 1226) or not (stratum I, n = 1641) based on the investigator's judgment.
  
  
  RESULTS
  The proportion of patients who suffered death or myocardial re-infarction at 30 days (primary outcome) was 12.2% in the fondaparinux vs. 15.1% in the control group, hazard ratio (HR) 0.80; 95% confidence interval (CI) 0.65-0.98. There was no increase in severe bleedings, HR 0.82; CI 0.44-1.55, or strokes, HR 0.62; CI 0.29-1.33. Consequently, the composite of death, myocardial re-infarction, or severe bleeding were significantly reduced at 30 days, HR 0.81; CI 0.67-0.99. Reductions in death or myocardial re-infarction at 30 days were consistent in stratum I with fondaparinux vs. placebo, HR 0.88; 95% CI 0.65-1.19, and in stratum II with fondaparinux vs. UF heparin infusion for 24-48 h (n = 806), HR 0.74; CI 95% 0.57-0.97, P = 0.41 for heterogeneity.
  
  
  CONCLUSIONS
  In STEMI patients not receiving reperfusion treatment, fondaparinux reduces the composite of death or myocardial re-infarction without an increase in severe bleedings or strokes as compared to placebo or UF heparin.
authors: Uppsala Clinical Research Center, Uppsala University Hospital, S-751 85 Uppsala, Sweden. jonas.oldgren@ucr.uu.se
authors: Jonas
authors: J
authors: Oldgren
authors: Lars
authors: L
authors: Wallentin
authors: Rizwan
authors: R
authors: Afzal
authors: Jean-Pierre
authors: JP
authors: Bassand
authors: Andrzej
authors: A
authors: Budaj
authors: Susan
authors: S
authors: Chrolavicius
authors: Keith A A
authors: KA
authors: Fox
authors: Christopher B
authors: CB
authors: Granger
authors: Shamir R
authors: SR
authors: Mehta
authors: Prem
authors: P
authors: Pais
authors: Ron J G
authors: RJ
authors: Peters
authors: Denis
authors: D
authors: Xavier
authors: Jun
authors: J
authors: Zhu
authors: Salim
authors: S
authors: Yusuf
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D000077425:Fondaparinux; D006470:Hemorrhage / Q000453:epidemiology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D011134:Polysaccharides / Q000627:therapeutic use*; D055502:Secondary Prevention; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux